Scientific Advisors and Consultants

Jason Kahn, Ph.D.
Jason Kahn is Associate Professor in the Department of Chemistry and Biochemistry at the University of Maryland College Park. He has 21 years of experience in DNA structure and topology; construction of nano-scale objects using DNA; and application of biophysical methods and computer simulation to complex systems. Dr. Kahn received his A.B. from Harvard and Ph.D. from Berkeley.

David H. Mathews, M.D., Ph.D.
David H. Mathews is Assistant Professor of Biochemistry and Chemistry at the University of Rochester. Dr. Mathews' work has been instrumental in helping Celadon's software better predict the role and impact of folding and cross hybridization of primers and probes. His work spans the fields of Computational Biology and Bioinformatics. His research focuses on predicting nucleic acid structure, developing computational tools for targeting RNA with pharmaceuticals, and using RNA as a pharmaceutical. Dr. Mathews has refined algorithms that predict folding and cross hybridization.

Cy A. Stein, M.D., Ph.D.
Cy A. Stein. is Professor of Medicine, Urology and Molecular Pharmacology at the Albert Einstein College of Medicine, and Head of the Medical Genitourinary Oncology Service at the Montefiore Medical Center in the Bronx, NY. He is a leader in antisense research and an expert in the treatment of human prostate and bladder cancer. He is the Co-Editor in Chief of Oligonucleotides and the author of 110 journal articles, 65 book chapters, reviews, and editorials.

David M. Rocke , PhD
David Rocke is Distinguished Professor of Biostatistics in the Department of Public Health Sciences at the University of California, Davis. He is a member of the UC Davis Genome Center, the UC Davis Cancer Center, and Co-Director of the Institute for Data Analysis and Visualization. A Fellow of the Royal Statistical Society, the American Stistical Association, and the American Association for the Advancement of Science, Dr. Rocke since 1996 has consulted with Celadon on statistical issues in connection with the Company's development of its Immunoassay analysis platform.